All bills

HB 1755-FN

relative to the 340B discounted drug purchasing program.

Filed 2026 · Referred for interim study · Health, Human Services and Elderly Affairs · Welfare/Medicare/Medicaid

Official record at gencourt.state.nh.us ↗

Open this bill in the searchable view →  ·  Follow this bill by RSS

On the record

Quoted from the General Court bill status page, not worked out from the docket.

StatusHOUSE
In the HouseINTERIM STUDY
Introduced1/7/2026
Floor date2/12/2026
LSR number3133
Local government impactno
Committee codeH09

Bill text (PDF) ↗

Where it stands

House: INTERIM STUDY

Every floor vote on this bill was a voice or division vote, so there is no record of how individual legislators voted.

A bill goes on the consent calendar when the committee vote was unanimous or nearly so, and any members who dissented did not object to placing it there. It then passes without floor debate. Ten members may file a petition to pull a bill off the consent calendar and have it debated and voted on separately.

In practice this often ends a bill's progress for the term.

Sponsors

Polozov, Yury(R) Merr 10, Litchfield, Melissa(R) Rock 32, Ulery, Jordan(R) Hills 13
Prime sponsor in bold. From the General Court sponsor file.

What happened

Every action recorded in the official docket, in order. Each line ends with the journal or calendar that recorded it; where we have the document, that citation links to it.

Votes

Roll call tallies and individual votes from the General Court roll call files. Presiding, excused and absent are shown separately: one member presides over each House roll call and does not vote except to break a tie.

Refer for Interim Study

February 12, 2026 · House · None–None, adopted

Decided on a voice vote. Only the outcome was recorded — there is no count of how any member voted.

Committee reports

Reproduced from the House Calendar in the committee’s own words.

Committee — REFER FOR INTERIM STUDY

Rep. Mark McLean

This bill requires participants in the federal 340B program to report transactional information to the Department of Health and Human Services and the Department of Justice on an annual basis as a hedge against fraud. The large pharmaceutical companies fund the program and provide subsidies allowing participating health care facilities to purchase drugs at a discounted price. In the case of Medicaid patients, the discount monies are passed on to the state’s Medicaid program. In the case of other patients, the facilities keep the difference between the price charged and the discounted price to invest in continuous improvement and other projects. The committee heard testimony that the state’s Medicaid program doesn’t currently have the bandwidth to implement a monitoring program due to resources being tied up in complying with federal Medicaid work requirements, but that they feel that the federal auditing conducted by HRSA (the Health Resources and Services Administration) is adequate to identify most fraud. The other concern expressed was that the added administrative burden might lead to facilities completely pulling out of the 340B program, effectively ending a revenue stream that Medicaid has come to rely upon. Understanding these considerations, but wanting to be certain that all avenues to prevent fraud have been explored, the committee recommends this bill be Referred for Interim Study. Vote 18-0.

Hearings and recordings

Recordings are the General Court’s own, on YouTube. Start times are estimates unless stated otherwise, and the player opens early.

Page generated 2026-09-03 from data published by the New Hampshire General Court. Granite Record is an independent project, not affiliated with the General Court. The official record always takes precedence. Corrections: [email protected]